Swiss longevity startup Avea receives 2.43 million euros in reinforcements

An increasing number of consumers are not only looking for supplements to increase health and vitamin levels, but have begun to actively invest in a longer healthy life. In order to cover this growing market, the Swiss-based start-up company for longevity supplements Avea has raised 2.43m euros in funding.

The startup is on a mission to extend the duration of human health with science-based supplements. It has attracted scientists and researchers in the field of longevity to produce a line of supplements to optimize long-term health, as well as to slow down and even reverse some of the signs of aging. The startup plans to use funding for expansion in Switzerland, Germany, Austria and the United Kingdom

Funding was led by Maximonbuilder of a longevity company and its longevity co-investment fund.

Avea launched its first products in February 2022. The company claims that its first formulation provides a synergistic combination of ingredients that reflects the latest research in the field of aging and health.

Co-founder and scientist Sophie Chablos He said: “Long-term health is an investment, not a cost. In addition to a balanced diet, regular exercise, hot and cold therapy and quality sleep, the longevity supplement regimen is essential for maintaining and optimizing the healthy aging process.

Dr. Tobias Reichmuth, serial entrepreneur and founder of Maximon, added: “The global longevity market is worth $ 8 trillion. The realm of longevity is the future of healthcare, and we believe that startups will play an important role in the industry. “